This page collects WhisperX intelligence signals tagged #pharmaceutical_industry. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
The $8 billion acquisition of Loxo Oncology by pharmaceutical giant Eli Lilly began not with a formal negotiation, but with a single white envelope slid across a conference room table. In December 2018, Loxo's leadership expected a casual catch-up with Lilly's head of oncology research. Instead, they walked into a room...
Pfizer's strategic pivot has hit a sudden reset. Andrew Baum, the former Citi investment banker brought in just six months ago to overhaul the pharmaceutical giant's post-pandemic direction, has abruptly departed his roles as Executive Vice President and Chief Strategy and Innovation Officer. His exit, confirmed by the...
Pfizer's strategic pivot has hit a sudden snag with the abrupt departure of Andrew Baum, the former Citibank analyst hired less than a year ago to redirect the pharmaceutical giant's course. Baum, who joined in June 2024 as Executive Vice President and Chief Strategy and Innovation Officer, has left his operational rol...